An Open-Label Exploratory Clinical Trial Evaluating the Effects of GLS (Coptidis Rhizoma-Evodiae Fructus 2 : 1) on Fibroblast Growth Factor 21 in Patients with Nonalcoholic Fatty Liver Disease

Table 3

Ultrasound-assessed the severity of hepatic fatty accumulation at baseline and the end of the study (n, %).

	Baseline				Z		End				Z
	Absent	Mild	Moderate	Severe			Absent	Mild	Moderate	Severe
GLS (n = 59)	0 (0)	18 (30.5)	20 (33.9)	21 (35.6)	−0.090	0.928	21 (35.6)	25 (42.4)	8 (13.6)	5 (8.5)	−2.634	0.008
PPC (n = 60)	0 (0)	16 (26.7)	24 (40.0)	20 (33.3)			8 (13.3)	30 (50.0)	15 (25.0)	7 (11.7)

The P values compare the severity of hepatic fatty accumulation at baseline and the end of the study between the two groups.